Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Feel Therapeutics Granted 2nd Patent for Emotion AI Technology


News provided by

Feel Therapeutics

May 16, 2024, 09:30 ET

Share this article

Share toX

Share this article

Share toX


Feel Therapeutics, the Digital Precision Medicine company for mental and behavioral health, today announces the recent granting of US Patent No. 11,967,339 by the United States Patent and Trademark Office, marking the company's achievement of its second patent milestone in Emotion AI technology. Entitled "Method for detecting and recognizing an emotional state of a user," this patent represents a significant development for Feel Therapeutics, extending the scope of its innovative and proprietary technology previously established in US Patent No. 11,410,682.

SAN FRANCISCO, May 16, 2024 /PRNewswire-PRWeb/ -- Leveraging AI to Detect Emotional Changes through Physiological Data from Wearables

San Francisco, CA, April 30, 2024 - Feel Therapeutics, the Digital Precision Medicine company for mental and behavioral health, today announces the recent granting of US Patent No. 11,967,339 by the United States Patent and Trademark Office, marking the company's achievement of its second patent milestone in Emotion AI technology. Entitled "Method for detecting and recognizing an emotional state of a user," this patent represents a significant development for Feel Therapeutics, extending the scope of its innovative and proprietary technology previously established in US Patent No. 11,410,682.

Feel Therapeutics Granted 2nd Patent for Emotion AI Technology

Post this

Feel Therapeutics' AI technology passively and continuously monitors physiological signals through a proprietary wearable device, mobile phone sensors, voice, video, and the Feel application to detect emotional changes. To ensure even more precise measurement of the user's mood state, Feel's wearable device incorporates several sensors, including a continuous electrodermal activity (EDA) sensor, Photoplethysmography (PPG), Skin Temperature, Inertial Measurements, as well as an Environmental Temperature and Humidity Sensor. These enhancements bolster the accuracy and reliability of emotion detection, minimizing the impact of external factors on collected physiological data.

This latest patent underscores Feel Therapeutics' unwavering commitment to decoding mental health through advanced technology. The Emotion Detection Technology developed by Feel Therapeutics integrates cutting-edge machine learning and signal processing algorithms and methods. These algorithms analyze a fusion of multimodal data such as physiological as well as voice & video data to develop emotion AI technology and identify patterns corresponding to specific emotional changes, offering personalized support and/or real-time therapeutic interventions.

Haris Tsirmpas, PhD, co-founder, and CTO of Feel Therapeutics, emphasized the significance of the new patent, stating, "This extension to our previous patent underscores Feel Therapeutics' ongoing commitment to pushing the boundaries of innovation in mental health AI technology. Our Emotion Detection Technology, powered by advanced AI algorithms that we have meticulously developed and refined, represents a pivotal tool for unraveling the intricacies of human emotion and delivering tailored support to individuals in need."

This patent exemplifies Feel's steadfast dedication to ushering in the era of digital precision medicine in psychiatry, neuroscience, and beyond. "Our patent further solidifies Feel Therapeutics' position as a leader in digital precision medicine for mental and behavioral health" stated George Eleftheriou, CEO and co-founder of Feel Therapeutics. "By continuously refining and expanding our proprietary technology, we aim to reinvent the way we diagnose, monitor, and care for mental health through continuous and passive monitoring."

Feel's patent for emotion detection through AI technology is a cornerstone of the expansive patent portfolio and intellectual property of the company, reflective of years of relentless innovation and expertise. In tandem with their ongoing advancements, including a robust portfolio focused on digital biomarkers for mental conditions such as depression, anxiety, ADHD as well as sleep and stress related conditions. Feel Therapeutics is steadfast in its mission to further enhance personalized, data-driven digital precision medicine for mental health.

About Feel Therapeutics:

Feel Therapeutics is a Digital Precision Medicine company bringing continuous and passive monitoring to reinvent the way we diagnose, manage, and care for mental health.

The company is backed by top-tier investors (e.g., Felicis, Anthemis, SOSV, Satori, et al.) and partners with several top Pharmaceutical companies and CROs to monitor patients 24/7/365 and deliver precise support or interventions.

For more information about our work in mental health care, visit www.feeltherapeutics.com.

Media Contact

Eri Christogianni, Feel Therapeutics, 30 6948952328, [email protected], https://www.feeltherapeutics.com/ 

LinkedIn

SOURCE Feel Therapeutics

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.